Geode Capital Management
LIMN icon

Geode Capital Management’s Liminatus Pharma LIMN Stock Holding History

Geode Capital Management’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$154K Buy
41,207
+38,439
+1,389% +$194K ﹤0.01% 3946
2026
Q2 		$15.3K Buy
2,768
+412
+17% +$3.56K ﹤0.01% 4395
2026
Q1 		$20.2K Buy
2,356
+1,055
+81% +$28.1K ﹤0.01% 4447
2025
Q4 		$39.7K Buy
1,301
+26
+2% +$1.44K ﹤0.01% 4274
2025
Q3 		$106K Sell
1,275
-2
-0.2% -$432 ﹤0.01% 4117
2025
Q2 		$712K Buy
+1,277
New +$717K ﹤0.01% 3440

Other funds holding LIMN

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Cheviot Value Management
Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

Geode Capital Management's LIMN Position: Q3 2026 in Review

Geode Capital Management increased its Liminatus Pharma (LIMN) stake by 1,389% in Q3 2026, buying an estimated $194K and bringing the position to 41,207 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3946.

Geode Capital Management first reported a position in LIMN in Q2 2025 and has held it in 6 quarters since. The position peaked at $712K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

  • Geode Capital Management held 41,207 shares of Liminatus Pharma worth $154K as of Q3 2026.
  • Geode Capital Management bought 38,439 Liminatus Pharma shares in Q3 2026, an estimated $194K.
  • Liminatus Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3946 holding.
  • Geode Capital Management first reported a position in Liminatus Pharma in Q2 2025 and has held it in 6 quarters since.
  • Geode Capital Management's Liminatus Pharma position peaked at $712K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.